Back to search

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

NCT02857946

PHASE1INTERVENTIONAL
Genuine Research Center, Egypt
24 participants
Started 2016-02 · Completed 2016-04
Status: Completed (as of 12-23-2025)

Conditions

Healthy

Interventions

DRUG: Prevaglip (linagliptin)DRUG: Trajenta (linagliptin)

Linked Papers (from SciSciNet-V2)

Total Papers3
Background
0
Result
0
Derived
0
Unknown
3
View on ClinicalTrials.gov

Total Citations Per Year

Brief Summary

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals \& Medical Appliances, Egypt) and Trajenta 5 mg tablets(Boehringer Ingelheim International GmbH, Germany) after a single oral dose administration of each to healthy adults under fasting conditions

Sort by:

Background Papers0

No background papers linked

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers3

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability
1987
2,396 citations
Sample size determination for bioequivalence assessment by means of confidence intervals.
1991
221 citations
On sample size calculation in bioequivalence trials.
2001
115 citations